Monitoring of WT1‐specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation

No abstract is available for this paper.

• Publication year

  2006

• Venue

  International Journal of Cancer

• Publication date

  2006-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.21960PMID 16596644
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas.

  2009cited by this paper
• Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.

  2005cited by this paper
• Differences in phenotype and function between spontaneously occurring melan‐A‐, tyrosinase‐ and influenza matrix peptide‐specific CTL in HLA‐A*0201 melanoma patients

  2005cited by this paper
• Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation

  2005cited by this paper
• Wilms' tumour gene 1 (WT1) in human neoplasia

  2005cited by this paper
• Review Articles (434 articles)

  2005cited by this paper
• Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity

  2004cited by this paper
• Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen.

  2004cited by this paper
• mRNA expression of leukemia‐associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies

  2004cited by this paper
• Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-γ-producing T cells

  2004cited by this paper
• Phenotypic classification of human CD8+ T cells reflecting their function: inverse correlation between quantitative expression of CD27 and cytotoxic effector function

  2004cited by this paper
• Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

  2004cited by this paper
• WT1 is a tumor‐associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells

  2004cited by this paper
• Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.

  2003influential reference
• The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes.

  2003cited by this paper
• Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.

  2003cited by this paper
• Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL.

  2002cited by this paper
• PRAME gene expression in childhood acute lymphoblastic leukemia.

  2002cited by this paper
• CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.

  2002influential reference
• Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis

  2001cited by this paper
• Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.

  2000cited by this paper
• Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

  2000cited by this paper
• Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

  2000cited by this paper
• Immunity to WT1 in the animal model and in patients with acute myeloid leukemia.

  2000cited by this paper
• A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response1

  2000cited by this paper
• Distribution of human CMV‐specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms

  1999cited by this paper
• Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.

  1999cited by this paper
• Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth

  1999cited by this paper
• Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism

  1999cited by this paper
• PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells

  1998cited by this paper
• Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma

  1998cited by this paper
• CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity.

  1998cited by this paper
• Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes

  1997influential reference
• Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.

  1997cited by this paper
• Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells

  1995cited by this paper
• The Wilms tumour gene WT1 is expressed in murine mesoderm–derived tissues and mutated in a human mesothelioma

  1993cited by this paper
• The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor

  1993cited by this paper
• Expression of the Wilms' tumor gene (WT1) in human leukemias.

  1992cited by this paper
• Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.

  1990cited by this paper

• Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse

  2023cites this paper
• WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML)

  2020cites this paper
• Role of cancer immunology in chronic myelogenous leukemia.

  2019cites this paper
• Therapeutic vaccine strategies to induce tumor-specific T-cell responses

  2019cites this paper
• PRAME peptide‐specific CD8+ T cells represent the predominant response against leukemia‐associated antigens in healthy individuals

  2018cites this paper
• Title Recent advance in antigen-specific immunotherapy for acutemyeloid leukemia

  2018cites this paper
• WT1 Peptide Vaccine for the Treatment of Malignancies: Its Development, Recent Progress, and Future Perspectives

  2016cites this paper
• Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients.

  2016cites this paper
• Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins.

  2016cites this paper
• Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects

  2014cites this paper
• CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.

  2014cites this paper
• Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.

  2013influential citation
• Tumor-Associated Antigens

  2013cites this paper
• Establishment of a stable T lymphoma cell line transduced with HLA-A*24:02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring.

  2013cites this paper
• Minor H antigens in GVHD and GVL Multi-center analyses demonstrate significant clinical effects of minor Histocompatibility antigens on GVHD and GVL after HLA matched related and unrelated stem-cell transplant Manuscript submitted for publication

  2012cites this paper
• Recent Advance in Antigen-Specific Immunotherapy for Acute Myeloid Leukemia

  2011cites this paper
• Posttransplantation vaccination: concepts today and on the horizon.

  2011cites this paper
• Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer

  2011cites this paper
• Evaluation of current cancer immunotherapy: hemato-oncology.

  2011cites this paper
• Allogeneic stem cell transplantation for renal cell carcinoma

  2011cites this paper
• Vaccines as consolidation therapy for myeloid leukemia

  2011cites this paper
• Allogeneic HLA-A*02–Restricted WT1-Specific T Cells from Mismatched Donors Are Highly Reactive but Show Off-Target Promiscuity

  2011cites this paper
• Off-Target Promiscuity Donors Are Highly Reactive but Show WT 1-Specific T Cells from Mismatched Restricted − Allogeneic

  2011cites this paper
• WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.

  2010cites this paper
• Graft-versus-host driven graft-versus-leukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients

  2010cites this paper
• Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions.

  2010cites this paper
• Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

  2010cites this paper
• Potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for the sustained remission of refractory AML

  2010cites this paper
• Development of a Wilms’ tumor antigen-specific T-cell receptor for clinical trials: engineered patient’s T cells can eliminate autologous leukemia blasts in NOD/SCID mice

  2010cites this paper
• Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

  2010cites this paper
• WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.

  2009cites this paper
• Does chemotherapy modify the immune surveillance of hematological malignancies?

  2009cites this paper
• Treatment with Soluble Fas Ligand VivoDisease-Mediating Human T Cells by Ex Selective Reduction of Graft-versus-Host

  2009cites this paper
• Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma

  2009cites this paper
• Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer.

  2009cites this paper
• Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand1

  2009cites this paper
• Streptamer technology allows to isolate leukemia antigen-specific CD8 + T cells

  2009cites this paper
• Induction of Wilms' Tumor Protein (WT1)–Specific Antitumor Immunity Using a Truncated WT1-Expressing Adenovirus Vaccine

  2009cites this paper
• Potential of dendritic cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide‐ and keyhole limpet hemocyanin‐pulsed, donor‐derived dendritic cell vaccine for acute myeloid leukemia

  2008cites this paper
• "Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further development.

  2008cites this paper
• Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation

  2008cites this paper
• WT1 peptide vaccine for the treatment of cancer.

  2008cites this paper
• Novel approaches in allogeneic stem cell transplantation

  2006cites this paper